 |
| Aeras and TuBerculosis Vaccine Initiative Strengthen Collaborative Efforts
New MOU aims to unify global efforts to develop new TB vaccines for the world |
|
|
Aeras and the TuBerculosis Vaccine Initiative (TBVI), a pan-European TB vaccine research foundation based in the Netherlands, signed a new memorandum of understanding this past week to tackle the major technical and scientific challenges that have plagued vaccine development since the introduction of the BCG vaccine more than 85 years ago. Over the past several years, increased investment in vaccine research and development has resulted in a robust pipeline of new generation TB vaccines. Enhanced collaboration between the two major TB vaccine development organizations will accelerate the development of this pipeline, creating efficiencies that will significantly increase the likelihood of having new vaccines available for use within the coming decade.
» Read the press release
|
 |
| Announcing the Third Global Forum on TB Vaccines
March 24-27, 2013 | Cape Town, South Africa |
|
|
The Third Global Forum on TB Vaccines will convene stakeholders from across sectors to review progress in TB vaccine research and development and strategize how to address critical issues in the field over the next decade. The Forum - which is co-organized by the TuBerculosis Vaccine Initiative, Aeras, and the South African Tuberculosis Vaccine Initiative of the University of Cape Town under the auspices of the Stop TB Partnership Working Group on New Vaccines - will follow on the very successful prior Global Forums in Geneva (2001) and Estonia (2010). Abstracts for oral and poster presentations are being accepted until October 1, 2012. Sponsorship opportunities and registration are also now available on the conference website.
» View the conference website
» Register online
» Submit an abstract
» View sponsorship opportunities
» Join the mailing list
|
 |
|
TB Vaccine Field Launches Strategic Blueprint
Blueprint details comprehensive strategy for developing and introducing effective TB vaccines |
|
| TB vaccine development has made advances that would have been unimaginable a decade ago. In recognition of World TB Day 2012, the journal Tuberculosis published a special issue - co-edited by Dr. Michael J. Brennan, Senior Advisor for Scientific and Global Affairs at Aeras, and Dr. Jelle Thole, Director of the TuBerculosis Vaccine Initiative - containing a new TB Vaccine Blueprint, editorials and opinion pieces. The Blueprint outlines five keys to progress: creativity in research and discovery; correlates of immunity and biomarkers for TB vaccines; clinical trials: harmonization & cooperation; rational selection of TB vaccine candidates; and the critical need for advocacy, community acceptance and funding. Opinion pieces were provided by preeminent researchers from the National Institute of Allergy and Infectious Diseases, the Bill & Melinda Gates Foundation, the World Health Organization, and other key research institutions.
» Read the press release and media coverage
» View the special issue of Tuberculosis: "Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade"
|
 |
World TB Day Raises Awareness about TB Vaccine Development
Aeras participates in events on three continents |
|
|
World TB Day - held March 24 each year in recognition of the day Dr. Robert Koch discovered the cause of tuberculosis - is a time to raise awareness about tuberculosis and the need for new drugs, diagnostics and vaccines to combat this disease. Aeras and our partners observed World TB Day 2012 by participating in events in Washington, DC; Brussels, Belgium and Johannesburg, South Africa to raise awareness about the need for new vaccines to prevent tuberculosis.
» View Aeras' World TB Day events page |
 |
Aeras Contract Manufacturing Launches New Website
New website features State-of-the-art manufacturing facility in Rockville, MD, USA |
|
|
Aeras' mission is to develop new TB vaccines and utilize our broad capabilities in collaboration with partners to support the development of vaccines and other biopharmaceuticals to address public health needs. In keeping with this mission, Aeras manufacturing is contracting with outside groups on process development and cGMP clinical manufacturing. Offering contract manufacturing services contributes to the sustainability of Aeras' in-house TB vaccine manufacturing programs while helping partners address their product and process development challenges as they scale to commercial manufacturing, utilizing a best-in-class cGMP certified facility with access to in-house technical expertise.
» Explore Aeras' contract manufacturing services
|
 |
Aeras Africa Office Celebrates Opening
Office relocates to Observatory in Cape Town, South Africa |
|
| Aeras Africa office has recently moved from Rondebosch to Black River Park Observatory in Cape Town, South Africa, to accommodate for growth in clinical trial development activities across Africa. Attending the open house ceremony on March 16th was Jim Connolly, Aeras' President and Chief Executive Officer, and Glaudina Loots, Director of Health Innovation at South Africa's Department of Science and Technology.
» Read more about the open house and view images
|
|
Press Coverage
| |
4.23.2012
Opinion: A TB Vaccine Blueprint
THE SCIENTIST
3.24.2012
South Africa launches TB test for gold miners (video)
AGENCE FRANCE-PRESSE
|
Support Us
| |
Every 20 seconds,
someone dies of TB.
These lives can be saved.
Your support will enable Aeras to continue cutting-edge research and train local partners.
Join us in the fight
against TB.
» make a donation
|
| | |
View Our Portfolio of Vaccine Candidates
Aeras Africa New Address: | |
Blackriver Park
First Floor
Old Warehouse Building
Observatory 7925
Cape Town
SOUTH AFRICA
+27 21 659 8440 |
|
|
